Achalasia Medical Services in China

Achalasia is a rare primary esophageal motility disorder characterized by the failure of the lower esophageal sphincter (LES) to relax adequately during swallowing, coupled with absent or ineffective peristalsis in the distal two-thirds of the esophageal body. This functional obstruction leads to progressive dysphagia (initially for solids, later for liquids), regurgitation of undigested food, retrosternal discomfort, and weight loss. Pathophysiologically, achalasia results from degeneration and loss of inhibitory ganglion cells—particularly nitric oxide synthase (NOS)- and vasoactive intestinal peptide (VIP)-expressing neurons—in the myenteric plexus of the esophagus. The exact etiology remains unclear but is thought to involve autoimmune, viral (e.g., herpes simplex virus-1, measles), and genetic components, with growing evidence of chronic inflammatory infiltration and neuronal apoptosis. Epidemiologically, achalasia affects approximately 1–1.6 per 100,000 individuals annually worldwide, with a prevalence of 10–12 per 100,000. It occurs equally across sexes and most commonly presents between ages 25 and 60, though pediatric and geriatric cases are documented. No definitive environmental or lifestyle risk factors have been established; however, familial clustering and associations with certain HLA haplotypes (e.g., HLA-DQB1*05:01) suggest a genetic predisposition. Autoimmune comorbidities—including type 1 diabetes, Sjögren’s syndrome, and thyroid disease—are observed more frequently than in the general population. Quality of life is significantly impaired: patients report chronic fatigue, social withdrawal due to meal-related anxiety and embarrassment, sleep disruption from nocturnal regurgitation and aspiration, and heightened risk of aspiration pneumonia and esophageal squamous cell carcinoma (with lifetime risk estimated at 2–7%). Untreated, symptoms worsen progressively, leading to esophageal dilation (megaesophagus), stasis, and structural remodeling. Early diagnosis—via high-resolution manometry (HRM), barium esophagram, and upper endoscopy—is critical to guide appropriate intervention and prevent irreversible esophageal damage.

Achalasia is a primary esophageal motility disorder characterized by absent peristalsis in the distal esophagus and impaired relaxation of the lower esophageal sphincter (LES) during swallowing. This results in progressive dysphagia for solids and liquids, regurgitation of undigested food, chest pain, and weight loss. Diagnosis relies on high-resolution manometry (HRM), which confirms the classic findings of pan-esophageal pressurization, absence of peristalsis, and incomplete LES relaxation (integrated relaxation pressure >15 mmHg). Barium esophagram typically shows a dilated, aperistaltic esophagus with a 'bird’s beak' tapering at the gastroesophageal junction, while upper endoscopy excludes mechanical obstruction or malignancy.

Conservative management plays a limited but pragmatic role—primarily as a bridge to definitive therapy or for patients who are poor surgical candidates. Lifestyle modifications include eating slowly, chewing thoroughly, drinking ample fluids with meals, avoiding late-night eating, and sleeping with the head of the bed elevated ≥30 degrees to reduce nocturnal regurgitation and aspiration risk. Patients should avoid foods that exacerbate symptoms (e.g., tough meats, raw vegetables, carbonated beverages) and refrain from lying supine within two hours of eating. While these measures do not alter disease progression, they improve symptom control and nutritional status, particularly in elderly or frail individuals.

Pharmacologic therapy has modest efficacy and is rarely used as first-line treatment. Nitrates (e.g., isosorbide dinitrate 2.5–5 mg sublingually 10–15 minutes before meals) and calcium channel blockers (e.g., nifedipine 10–20 mg orally before meals) induce transient LES relaxation via smooth muscle vasodilation. However, their effects are short-lived (30–60 minutes), tolerance develops rapidly, and systemic side effects—including headache, hypotension, and peripheral edema—limit long-term adherence. Botulinum toxin A (Botox®) injection into the LES under endoscopic guidance provides more sustained relief (median duration 6–12 months) by inhibiting acetylcholine release from myenteric plexus neurons. Though minimally invasive and well-tolerated, Botox is reserved for high-risk patients (e.g., severe cardiopulmonary comorbidities, advanced age >80 years) due to its temporary effect and potential to complicate subsequent surgical myotomy via fibrosis. Repeat injections yield diminishing returns and are not recommended beyond two sessions.

Definitive therapy centers on reducing LES resistance. Pneumatic dilation (PD) remains a cornerstone non-surgical intervention. Under fluoroscopic or endoscopic guidance, a calibrated balloon (typically 30–40 mm) is inflated across the LES for 60–90 seconds, inducing controlled tearing of circular muscle fibers. Success rates range from 70% to 90% at one year, though recurrence occurs in ~30% of patients by five years. Major risks include perforation (1–3%), which mandates immediate surgical consultation, and gastroesophageal reflux disease (GERD) in up to 30% of cases—necessitating lifelong proton pump inhibitor (PPI) therapy and surveillance for Barrett’s esophagus. PD is contraindicated in patients with prior failed myotomy or suspected esophageal diverticula.

Surgical treatment offers durable symptom control. Laparoscopic Heller myotomy (LHM) with partial fundoplication (typically Dor or Toupet) is the gold standard for fit patients. The procedure involves lengthwise division of the LES and distal esophageal circular muscle (≥2 cm proximal, ≥2 cm distal to the GEJ), followed by an antireflux wrap to mitigate postoperative GERD. Meta-analyses report >90% long-term success, with symptom resolution sustained in >85% at 10 years. Robotic-assisted LHM is increasingly adopted in tertiary centers, offering enhanced dexterity and visualization—particularly beneficial in obese or anatomically complex patients. Peroral endoscopic myotomy (POEM) represents a major advancement: an incisionless, transoral endoscopic technique creating a submucosal tunnel from 10–12 cm proximal to the GEJ, followed by circumferential myotomy of the LES and distal esophagus. POEM achieves comparable efficacy to LHM (>90% symptom improvement at 2 years), with shorter hospital stays (1–2 days), faster return to normal activity (<1 week), and no external incisions. However, it carries a higher incidence of post-procedure GERD (up to 45%), requiring routine pre- and postoperative pH-impedance testing and vigilant PPI use. Both LHM and POEM require expertise; outcomes correlate strongly with operator volume and institutional experience.

China offers distinct advantages in achalasia management. First, China hosts some of the world’s highest-volume centers for POEM—pioneered by Dr. Pinghong Zhou in Shanghai—and maintains rigorous national training standards through the Chinese Society of Gastrointestinal Endoscopy. Second, integrated multidisciplinary care is standardized: HRM, timed barium swallow, endoscopy, and pH-impedance testing are routinely available in tier-3 hospitals, enabling precise phenotyping (e.g., Chicago Classification subtypes I–III) to guide personalized therapy selection. Third, cost-effectiveness is notable: POEM and LHM are widely covered under China’s Basic Medical Insurance, with out-of-pocket expenses significantly lower than in Western countries. Fourth, rapid innovation adoption is facilitated by streamlined regulatory pathways—the National Medical Products Administration (NMPA) approved next-generation endoscopic platforms (e.g., dual-channel therapeutic endoscopes with real-time elastography) within 12 months of CE/US FDA clearance. Finally, longitudinal follow-up is robust: national registries track >50,000 achalasia patients, supporting evidence-based refinements in postoperative GERD monitoring and nutritional rehabilitation protocols.

Post-treatment recovery emphasizes structured re-feeding and vigilant surveillance. After PD or surgery, patients begin clear liquids on post-procedure day one, advancing to soft, non-fibrous foods over 7–10 days. Solid foods are reintroduced gradually over 3–4 weeks; meat, bread crusts, and raw produce are avoided for ≥6 weeks. All patients undergo repeat HRM and/or timed barium swallow at 3 months to assess functional improvement. GERD screening via ambulatory pH-impedance is mandatory at 6 months and annually thereafter. Nutritional counseling is integral: registered dietitians assess caloric intake, screen for micronutrient deficiencies (especially iron, vitamin B12, and fat-soluble vitamins), and recommend oral supplements if needed. Patients are advised to maintain upright posture for ≥30 minutes after meals, avoid tight waistbands, and report alarm symptoms—new-onset odynophagia, hematemesis, or unexplained weight loss—promptly, as these may indicate complications or alternative diagnoses. Long-term prognosis is excellent with appropriate intervention: >95% of treated patients achieve meaningful symptom relief and preserved quality of life, underscoring the importance of timely referral to specialized digestive disease centers.